# Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers

> **NCT02291471** · PHASE1 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Rheumatic Diseases

## Interventions

- **DRUG:** T0001，10mg
- **DRUG:** T0001，20mg
- **DRUG:** T0001，35mg
- **DRUG:** T0001，50mg
- **DRUG:** T0001，65mg
- **DRUG:** T0001，75mg

## Key facts

- **NCT ID:** NCT02291471
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291471, "Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02291471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*